SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is a major talking point after recently dipping below a significant price level, sparking intense debate among investors. While many are voicing extreme bearish sentiment, labeling it a 'scam' and anticipating further declines, a strong contingent sees the current pullback as a strategic accumulation chance, citing oversold conditions and recent institutional comparisons to gold.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is actively trending after launching a low-cost compounded version of the Wegovy weight-loss pill and a new multi-cancer early detection test, sparking investor debate over potential market disruption and a short squeeze versus significant litigation risks and margin pressure.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is generating significant buzz following a reported earnings beat and the authorization of a stock repurchase, sparking active community discussions around its current undervaluation, future growth potential given user trends, and the broader market's muted reaction.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is heavily trending ahead of its anticipated earnings report, with community discussion focused on whether strong AWS growth, driven by massive AI investments, can overcome broader market skepticism that has recently punished other tech giants post-earnings, alongside concerns about new regulatory fines and recent layoffs.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet (GOOGL) is trending following strong Q4 earnings, particularly driven by accelerating Google Cloud and Search revenue. However, its substantial increase in planned capital expenditure for AI infrastructure is sparking debate among investors, with some viewing it as a strategic move for future dominance and others expressing concern over potential margin impact.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending as the community eagerly awaits an imminent Japan PMDA approval for its innovative Alpha DaRT cancer treatment, fueled by strong pancreatic cancer trial data, growing institutional interest, and a widespread belief that the stock is significantly undervalued and poised for a major breakout.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending following its earnings report, which showcased strong growth in cloud services, but also unveiled higher-than-expected capital expenditure guidance for AI infrastructure. The community is actively debating if this increased spending is a strategic move for future AI dominance or a short-term profitability concern, leading to a mixed market reaction.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is actively discussed as its imminent earnings report coincides with a significant Bitcoin price drop, fueling community concerns over substantial unrealized losses, potential liquidations, and bankruptcy risks on its leveraged crypto holdings, though some view the downturn as a buying opportunity.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing a significant sell-off after an unexpectedly cautious 2026 outlook, citing intensifying competition and U.S. drug pricing pressures. The market is reacting sharply despite strong early uptake of its oral Wegovy pill, especially as Hims & Hers also announced plans for a cheaper, compounded semaglutide.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Kelly Services' Class B shares are experiencing extraordinary volatility and multiple trading halts, fueled by news of Hunt Equity Opportunities acquiring a controlling stake in the low-float voting shares. The community is actively debating the sustainability of these parabolic gains and watching for potential sympathetic movement in its Class A shares.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective on shares of Sagimet Biosciences in a research report on Tuesday...

Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Guggenheim

Guggenheim started coverage on shares of Sagimet Biosciences in a report on Tuesday. They set a "buy" rating and a $27.00 target price on the stock...

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne Ascletis Announces Positive Topline...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight ratings firms that are covering the company, MarketBeat...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the stock...

Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 5.4% - Still a Buy?

Sagimet Biosciences (NASDAQ:SGMT) Trading Up 5.4% - Time to Buy...

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment Ascletis Announces...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine brokerages that are covering the company, Marketbeat reports. One...

Sagimet Biosciences (NASDAQ:SGMT) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Sagimet Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...

Insider Selling: Sagimet Biosciences (NASDAQ:SGMT) Chairman Sells 37,688 Shares of Stock

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) Chairman George Kemble sold 37,688 shares of the company's stock in a transaction on Thursday, November 20th. The shares were sold at an...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMZN earnings on Thursday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.42	--	--	N/A
Q3 '25	-$0.39	-$0.40	-3.63%	MISSED
Q2 '25	-$0.51	-$0.32	37.05%	BEAT
Q1 '25	-$0.67	-$0.56	15.91%	BEAT
Q4 '24	-$0.62	-$0.50	19.52%	BEAT

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest SGMT News

SGMTSagimet Biosciences Inc